Meta-analysis of shotgun sequencing of gut microbiota in obese children with MASLD or MASHOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This meta-analysis examined the gut microbiome in obese children with metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH). Researchers searched electronic databases for studies providing shotgun metagenomic sequencing data on the gut microbiome in children with obesity, with or without MASLD or MASH. The analysis combined data from multiple existing studies with an additionally recruited cohort to compare microbiome composition and function across disease states.
Who was studied?
The pooled analysis included obese children with MASLD (n = 153) and MASH (n = 70), compared against obese children without liver disease (n = 58) and healthy controls (n = 132). This population was assembled from nine identified studies plus one additionally recruited cohort, all using shotgun metagenomic sequencing. The study therefore draws on a multi-cohort pediatric dataset rather than a single trial population.
What were the most important findings?
Fecal microbiomes of children with MASLD and MASH differed significantly in alpha- and beta-diversity compared to obese and healthy children (p < 0.001). Faecalibacterium prausnitzii and Prevotella copri were differentially abundant across the obese, MASLD, and MASH groups. Machine-learning models (XGBoost and random forest) accurately distinguished MASLD from obesity (AUROC 87%) and MASH from MASLD (AUROC 89%), with pathway-abundance-based models performing similarly well (81% and 88%, respectively). Increasing hepatic fibrosis was accompanied by further gut microbiome alteration and a concomitant rise in Prevotella copri abundance (p = 0.0082).
What are the greatest implications of this study?
The findings suggest that gut microbiome composition, including shifts in species such as Faecalibacterium prausnitzii and Prevotella copri, tracks with the progression from obesity to MASLD to MASH and fibrosis severity in children. The high predictive accuracy of microbiome-based machine-learning models points to potential non-invasive tools for staging pediatric liver disease. These results also support the gut microbiome as a plausible target for future diagnostic or therapeutic strategies in pediatric metabolic liver disease.